Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus NORETHINDRONE AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus NORETHINDRONE AND ETHINYL ESTRADIOL.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs NORETHINDRONE AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Thickens cervical mucus to inhibit sperm penetration. Alters endometrium to reduce implantation likelihood.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
One tablet (norethindrone 1 mg / ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 13-27 hours (terminal, mean ~17 hours). Half-life supports once-daily dosing for contraceptive efficacy.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Norethindrone: ~50% renal (as metabolites), ~50% fecal (biliary). Ethinyl estradiol: ~40% renal, ~60% fecal (primarily as glucuronide conjugates).
Category D/X
Category D/X
Progestin + Estrogen
Progestin